Medical Letter on the CDC & FDA
Publisher: CW Henderson
Issue: August 4, 2002
Page: 2

Breast Cancer
Study finds no link to oral contraceptive use for women 35 and over

2002 AUG 4 - (NewsRx.com) -- Women who took oral contraceptives at some point in their lives are no more likely to develop breast cancer between the ages of 35 and 64 than are other women the same age, according to findings from the National Institute of Child Health and Human Development (NICHD) Women's Contraceptive and Reproductive Experiences Study (Women's CARE).

The study appears in the June 27, 2002, issue of the New England Journal of Medicine. The analysis was conducted by Polly A. Marchbanks of the U.S. Centers for Disease Control and Prevention (CDC) and colleagues at NICHD and other research institutions around the country in order to determine whether current or former contraceptive use during the reproductive years increases breast cancer risk. The women studied are members of the first generation of American women to use oral contraceptives.

"Women between the ages of 35 and 64 are more likely to develop breast cancer than are younger women," said Duane Alexander, MD, Director of the NICHD. "It is very reassuring that the NICHD Women's CARE study found no increase in breast cancer risk among past or present oral contraceptive users in this age group."

The researchers interviewed more than 9200 white and black women between the ages of 35 and 64 living in Atlanta, Detroit, Philadelphia, Los Angeles and Seattle. Roughly half of the study participants had recently been diagnosed with breast cancer, while the other half did not have a diagnosis of breast cancer. The women were interviewed in person and asked a series of questions about their use of oral contraceptives and other hormones as well as their reproductive, health and family issues.

"This has been a concern for women who use oral contraceptives," said CDC Acting Director David Fleming, MD. "Previous studies have shown that for healthy women who do not smoke, the health benefits of oral contraceptives far exceed the health risks. This study should ease women's fears about oral contraceptives and breast cancer risk."

Compared with women who had never used oral contraceptives, women who had used any type of oral contraceptive did not have a greater risk of developing breast cancer. Furthermore, examination of multiple aspects of oral contraceptive exposure (ever, current, or former use, duration of use, age at first use, time since last use, and use by estrogen dose) revealed little evidence that oral contraceptives increase breast cancer risk. Oral contraceptive use among women with a family history of breast cancer was not associated with a significantly increased breast cancer risk, nor was the initiation of oral contraceptive use at a young age. Results were generally similar across age and racial groups.

"These results are good news," Marchbanks said. "For women 35-64 years old, this study provides reassurance that oral contraceptives do not increase the risk of breast cancer."

Approximately 80% of U.S. women born since 1945 have used oral contraceptives. There has been some concern in the past about the possible effect of oral contraceptive use on breast cancer risk. In fact, a 1996 formal review of 54 smaller studies conducted over the past 25 years found a slightly increased risk of breast cancer in women who were current or recent users of oral contraceptives. Other previous studies did not find an increased risk of breast cancer among oral contraceptive users.

"Large numbers of women who took oral contraceptives during their reproductive years are now reaching the ages of greatest breast cancer risk," said Robert Spirtas, DrPH, chief of NICHD's Contraception and Reproductive Health Branch and one of the authors of the study. "We conducted this study to resolve the long-standing concern that oral contraceptive use might be associated with an increased risk of breast cancer in later life. Our study provides scientific evidence that there is no such association."

The research centers participating in the NICHD Women's CARE Study were Emory University in Atlanta, Fred Hutchinson Cancer Research Center in Seattle, Karmanos Cancer Institute at Wayne State University in Detroit, University of Pennsylvania in Philadelphia, and University of Southern California in Los Angeles. The CDC was the Data Coordinating Center.

The study was funded by the NICHD with additional financial support from the National Cancer Institute (NCI). The CDC contributed computer support and staffing.

This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. Copyright 2002, Medical Letter on the CDC & FDA via NewsRx.com.